FININ2MIN · BUSINESS PLAYBOOKS · PCJ-23
Retail Pharmacy & Jan Aushadhi
India guide to Retail Pharmacy & Jan Aushadhi: demand tests, setup, permissions, operating process, finance, risks, 24 FAQs and editable records.
General business education. Use the activity, location and transaction facts for legal and tax decisions; illustrative figures are not promised returns.
The business decision in two minutes
Operate a lawful community pharmacy with the appropriate retail drug permissions, qualified pharmacist coverage, authentic procurement, storage controls and prescription processes. A Jan Aushadhi Kendra is a specific programme route, not a substitute for a retail drug licence. This is distinct from running a clinic, an online medicine marketplace, a wholesale depot or manufacturing medicines.
| First decision | Practical answer |
|---|---|
| Customer and offer | Select authorised suppliers and assortment; pharmacist coverage, storage and stock discipline drive service quality. |
| Launch constraint | Product categories and activity determine the required State drug permissions. |
| Money driver | Contribution per customer baskets: realised price minus complete variable cash cost. |
| Stop condition | Do not launch a regulated or unsafe activity before its actual permissions, competence and safeguards are established. |
Demand signals and a local validation plan
The official Jan Aushadhi programme provides an established affordable-medicine retail channel. Its existence supports a service-need and channel opportunity, not a guaranteed return for a particular shop. Site demand depends on lawful customer access, nearby supply, product availability, prescription patterns, patient trust and the cost of maintaining qualified staffing and inventory.
Primary reference: PMBI — programme and official notices. The local validation plan and commercial recommendations are Finin2min’s analysis.
Study a realistic catchment, lawful referral opportunities, competitor service gaps and availability of qualified pharmacists. Obtain supplier terms and a stock list based on expected demand. Test cash economics without scheme incentives and with slow-moving stock. Avoid paying a large lease premium before premises suitability and the licensing route are settled.
| Evidence to collect | Why it matters |
|---|---|
| Paid pilot or signed mandate | A willingness to pay and an authorised buyer are stronger than likes, enquiries or a policy announcement. |
| Competitor and supplier checks | Compare service gaps, actual quotations, lead times and support rather than assuming an empty market. |
| Repeat and collection evidence | Validate retention, returns, service effort and cash collection before projecting a full year. |
| Downside test | Stress volume, pricing, costs and delay together; keep the decision reversible while uncertainty is high. |
Selection is an editorial opportunity assessment, not a measured national top-ten ranking, search-volume study or guaranteed-demand claim.
Choose the operating model
| Model | How the obligations and economics change |
|---|---|
| Independent community pharmacy | Select authorised suppliers and assortment; pharmacist coverage, storage and stock discipline drive service quality. |
| Jan Aushadhi Kendra | Follow PMBI’s operative approval and operating arrangements in addition to applicable drug permissions. |
| Specialised retail assortment | Focus on a permitted category or customer need; cold-chain and controlled products need additional safeguards and cannot be casually added. |
Start-to-operation process
Map the retail scope
List the drug and non-drug categories proposed, whether any controlled or cold-chain products are included, and whether delivery is contemplated. Separate retail from wholesale, online-platform activity and clinical services. Seek a State Drugs Control determination where scope changes the licence route. Do not assume a generic trade registration authorises medicine sales.
Completion evidence: Category and licence-scope matrix.
Choose a suitable premises
Check lawful possession, commercial use, layout, storage, power reliability, security and accessibility with the licensing requirements in mind. Make major lease commitments conditional on suitability. Record which party funds alterations and what happens if the premises cannot obtain the intended permission.
Completion evidence: Premises suitability file and conditional lease.
Secure qualified pharmacist coverage
Verify the professional registration and role required for the proposed operation with the relevant authority. Plan actual operating-hours coverage, leave and replacement. Do not rent a certificate or claim a pharmacist is present when absent. Payroll and relief costs belong in the business case before setting opening hours.
Completion evidence: Registration verification and coverage roster.
Complete the prescribed application
Use the competent State authority’s official route for the required retail permissions. Prepare entity, premises, professional and other requested documents and pay the assessed official fee. Respond to inspection or document queries and obtain the granted scope and conditions. An application receipt alone is not permission to begin restricted sales.
Completion evidence: Application, inspection queries and granted licence.
Assess PMBI participation separately
For a Kendra, review current PMBI application, premises, procurement, branding and operating conditions. Reconcile any incentive using the operative approval/circular and actual eligibility, not an old promotional cap or assumption. The base financial model excludes incentive receipts so that retail performance is visible on its own.
Completion evidence: PMBI approval/contract and operating conditions if chosen.
Procure authentic traceable stock
Use authorised and verified suppliers, preserve invoices and track batch, expiry and storage requirements. Set receipt checks and quarantine discrepancies. Avoid unidentified discounted inventory or unauthorised substitution. Establish supplier return and recall arrangements before accumulating stock that the shop cannot safely store or sell.
Completion evidence: Supplier approvals and stock receipt records.
Set dispensing and storage controls
Have the responsible qualified professionals establish lawful prescription and dispensing procedures for the authorised categories. Maintain required records, temperature controls and separation of non-saleable stock. Staff must not diagnose, alter treatment or dispense restricted items outside lawful conditions merely to secure a sale.
Completion evidence: Dispensing protocol and storage logs.
Operate transparent billing and service
Issue appropriate bills and maintain required sale records. Explain price, availability, return policy and escalation without making unsupported medical claims. Protect prescription and customer information. Reconcile daily cash, digital payments, stock movement and any programme ordering system; investigate shortages promptly.
Completion evidence: Daily sales/stock reconciliation and customer terms.
Manage expiry and recalls
Review near-expiry stock by batch, maintain a quarantine area and follow authorised return/disposal channels. Act promptly on supplier or regulator recall instructions. Record quantities held, supplied, returned and disposed. Expired stock should never return to saleable inventory through relabelling or an undocumented transfer.
Completion evidence: Expiry dashboard and recall completion record.
Review assortment and renewal obligations
Analyse availability, gross contribution after write-offs, pharmacist coverage and working-capital use. Renew or maintain licences and programme permissions as applicable and update material changes through the official process. At closure arrange lawful stock transfer/disposal and retain records rather than selling restricted inventory informally.
Completion evidence: Periodic compliance review and closure/transfer plan.
Permissions, prescribed forms and fees
| Decision | Trigger and scope | Authority / route | Form, fee and evidence |
|---|---|---|---|
| Retail drug permission | Product categories and activity determine the required State drug permissions. | Competent State Drugs Control authority and operative Drugs Rules. | Obtain the actual prescribed application, licence scope and fee assessment; no universal form/fee is assumed in this guide. |
| Pharmacist and premises | Professional coverage, storage and premises conditions are integral to lawful operation. | State Pharmacy Council/Drugs Control and relevant local premises authorities. | Verify registration and working arrangement; a copied credential is not evidence of actual coverage. |
| Jan Aushadhi approval | Programme participation adds its own eligibility and operating terms. | PMBI’s official application and operative approval/circulars. | Track scheme charges, margins and incentives separately from State licence fees and retail sales; no guaranteed incentive is modelled. |
| Special categories and channels | Controlled medicines, cold-chain items, delivery or wholesale can change requirements. | Competent drug authority and category-specific law. | Do not add these categories on the strength of a general retail-business guide; record the separate permission and operating controls. |
Do not mix fees with commercial costs
Tax, invoicing and accounting decisions
| Transaction | What to determine |
|---|---|
| Medicine and non-medicine sales | Determine GST classification by actual product and operative notification. Do not apply one assumed rate to all medicines, devices, supplements and cosmetics. |
| Trade schemes and returns | Reconcile purchase discounts, credit notes, expiry returns and customer refunds. Gross margin should reflect net purchase cost and losses rather than a headline programme percentage. |
| Programme incentive | Keep conditional scheme receipts separate from normal retail revenue and assess their accounting/tax treatment. No incentive is included in the workbook base case. |
| Professional and payroll costs | Classify genuine employment and contracted services correctly and comply with applicable withholding/payroll obligations. A borrowed registration certificate is not a legitimate staffing solution. |
Financial model: profit, funding and cash
| Input / result | Illustration | Interpretation |
|---|---|---|
| Monthly volume | 3,000 customer baskets | Actual billable output, not leads or theoretical production. |
| Net realised unit price | ₹350 | After commercial reductions; excluding indirect tax. |
| Variable cash cost / unit | ₹280 | Include applicable direct cost, rework, returns and service effort. |
| Fixed monthly cash cost | ₹150,000 | Staff/supervision, rent and recurring overhead in this scenario. |
| Safe/saleable monthly capacity | 6,000 customer baskets | Editable planning assumption, not a technical certificate. |
| Unit contribution | ₹70 | Net price less variable cash cost. |
| Operating break-even | 2,143 customer baskets | Fixed cost / contribution, rounded up; excludes financing and tax. |
| Equipment / installed assets | ₹450,000 | Illustrative capital expenditure. |
| Refundable startup deposits | ₹180,000 | Cash funding but not immediately an operating expense. |
| Pre-opening expense | ₹120,000 | Illustrative non-recurring launch expense. |
| Opening cash reserve | ₹650,000 | Starting liquidity; the forecast may show more funding is needed. |
| Initial funding before loan | ₹1,400,000 | Assets + deposits + pre-opening expense + opening cash. |
Worked calculation: 3,000 × (₹350 − ₹280) = ₹210,000 contribution; less ₹150,000 fixed cash cost leaves ₹60,000 before depreciation, finance, income tax and capital spending.
| Stress case | Monthly operating cash result | What it tests |
|---|---|---|
| Base illustration | ₹60,000 | The assumptions above. |
| Volume −20% | ₹18,000 | Volume is rounded to a whole billable unit, consistently with the workbook. |
| Price −10% | ₹-45,000 | Pricing pressure with costs unchanged. |
| Variable cost +10% | ₹-24,000 | Direct cost pressure with price unchanged. |
| Combined: volume −20%, price −10%, variable cost +10% | ₹-133,200 | An adverse combination, not a forecast probability. |
A margin promise does not finance advance stock payments
A pharmacy budget assumes generous supplier credit because the monthly gross margin appears sufficient. The selected procurement arrangement requires part of the payment before dispatch and the remainder on a shorter timetable.
Work through the decision
Use the actual supplier terms and separate independent retail procurement from PMBI programme arrangements. Reconcile ordering, advance payment, delivery, pharmacist availability, storage and prescription controls. Track batch expiry and return eligibility rather than assuming all unsold stock is refundable.
What to establish before proceeding
Stress the cash forecast at lower supplier credit and slower sales before accepting the opening assortment. Keep incentives outside the base cash case until the eligibility, sanction and payment timing are evidenced. Programme participation does not replace the applicable retail-drug permission or pharmacist coverage.
This example is Finin2min’s operating analysis. Its commercial assumptions are not quoted market terms or a permit determination.
Contracts, people and operating controls
Supplier contracts should cover authorised supply, batch traceability, recalls, cold-chain responsibility, expiry returns and credit. The lease should reflect the permitted premises use. PMBI participation, where chosen, requires its own operative agreement; do not promise scheme incentives in customer or lender materials without an established basis.
Assign responsibility before selling
Employment reference: Ministry of Labour / PIB — Labour Codes commencement and transition.
Make customer acquisition evidence-led
Study a realistic catchment, lawful referral opportunities, competitor service gaps and availability of qualified pharmacists. Obtain supplier terms and a stock list based on expected demand. Test cash economics without scheme incentives and with slow-moving stock. Avoid paying a large lease premium before premises suitability and the licensing route are settled.
Weekly operating dashboard
| Operating measure | How to use it |
|---|---|
| Expiry exposure | Cost of stock approaching expiry net of only documented and enforceable return rights. |
| Cash-funded stock days | Inventory holding funded by the pharmacy after supplier credit and advance-payment requirements. |
| Covered dispensing hours | Business hours with the required competent/pharmacist coverage, evidenced by actual rosters. |
Common failures and practical remedies
| Situation | Response | Boundary |
|---|---|---|
| Pharmacist coverage becomes unavailable | Use the lawful contingency for the affected scope and hours; arrange qualified replacement and notify the authority where required. | Never falsify attendance or continue restricted activity on a paper-only arrangement. |
| A product recall is received | Identify affected batches, stop supply, quarantine stock and follow authorised recall instructions with traceable quantity reconciliation. | Do not treat the recall as a routine commercial return. |
| Cold-chain storage fails | Quarantine potentially affected stock and obtain competent disposition advice based on product requirements and evidence. | Do not restore stock to sale merely because the refrigerator is cold again. |
| Slow stock consumes all cash | Reduce assortment based on demand, use legitimate supplier return terms and maintain an expiry plan. Reassess purchasing before missing payroll or licence obligations. | A full shelf is not the same as a healthy business. |
A practical 30/60/90-day launch plan
| Period | Specific milestone |
|---|---|
| Days 1–30 | Confirm the retail licence and pharmacist plan; choose independent or programme procurement on its actual terms. |
| Days 31–60 | Set batch/expiry records, storage controls, prescription handling and advance-payment funding. |
| Days 61–90 | Reorder from sale-through and expiry risk; reconcile incentive and supplier-credit assumptions against documents. |
Your launch controls
0 of 10 launch controls marked complete on this device.
Closure, transfer and business continuity
Use the prescribed change/closure process, arrange lawful transfer or disposal of stock, settle supplier and employee dues, protect prescription records and complete programme exit requirements where relevant. Do not transfer a licence informally with the shop keys.
Frequently asked questions
24 answers shown
Does PMBI approval replace a drug licence?
No. The programme’s official requirements include the appropriate retail drug licence and qualified pharmacist arrangements. Treat the Kendra route as an additional operating framework rather than a substitute for statutory permissions.
Can a non-pharmacist own the business?
Ownership and professional operation are different questions. Check the permitted entity and licensing conditions with the State authority and arrange genuine qualified pharmacist coverage. Ownership does not authorise the owner to perform restricted professional functions.
Can I use another pharmacist’s certificate while they work elsewhere?
Do not rely on a paper-only arrangement. The shop must meet the actual professional coverage and licensing conditions. Verify the working relationship, availability and permitted arrangements with the relevant authority.
Are Jan Aushadhi incentives included in the forecast?
No. The base case excludes them. Scheme notices and individual approval conditions may change eligibility, caps or timing, so add an incentive only when the operative basis and expected receipt are evidenced separately.
How much opening stock should I buy?
Base it on the permitted assortment, realistic demand, replenishment lead time and return terms. Stage orders rather than filling shelves indiscriminately. Model expiry and slow-moving inventory and protect cash needed for qualified staffing.
Can all medicines be sold without a prescription?
No. The responsible pharmacist must apply the requirements for the actual drug category and sale. Do not use a generic retail process for restricted products or permit sales staff to bypass prescription and record controls.
Can the shop advertise guaranteed cures?
Avoid unsupported medical claims and unqualified diagnosis or treatment advice. Product promotion and customer guidance must remain within applicable law and professional scope. Commercial pressure is not a basis to change a patient’s treatment.
What happens to expired medicines?
Separate them from saleable stock and use the authorised return or disposal process with records. Do not erase expiry information, mix them into current stock or sell them through informal channels to recover a loss.
Is home delivery automatically covered?
Do not assume that a retail licence settles every delivery or online arrangement. Confirm the applicable rules, prescription handling, storage, records and service area for the exact channel before advertising it.
How do I calculate pharmacy margin?
Use net sales excluding tax less actual product cost, returns, expiry losses and variable charges. Then deduct qualified staffing, rent, utilities and other fixed costs. A headline trade margin is not net profit.
Can I add medical equipment or supplements?
Classify each addition separately. Devices, foods/supplements and drugs can follow different regimes and tax treatment. Assess the actual product, premises scope, labels and supplier before extending the assortment.
What should be checked before buying an existing pharmacy?
Review granted permissions and transfer/change requirements, pharmacist arrangements, supplier dues, batch/expiry stock, recalls, lease rights and tax records. Do not assume that purchasing fixtures automatically transfers the licence or programme approval.
What initial funding does the retail pharmacy & jan aushadhi illustration use?
The illustration uses ₹450,000 of equipment/setup assets, ₹180,000 of refundable deposits, ₹120,000 of pre-opening expense and ₹650,000 of opening cash: ₹1,400,000 before any extra shortfall identified in the monthly forecast. These are modelling assumptions, not quotations, government fee schedules or a recommended investment amount. Replace them with itemised local evidence.
How is the monthly operating result calculated for PCJ-23?
At 3,000 customer baskets, a net price of ₹350 and variable cost of ₹280 per unit give ₹210,000 contribution. After ₹150,000 fixed cash costs, the illustrative surplus is ₹60,000 before depreciation, finance, income tax and capital spending. It is not guaranteed profit or a tax computation.
What is the break-even volume in the PCJ-23 example?
Fixed cash costs divided by unit contribution gives 2,143 customer baskets, rounded up. This operating break-even excludes financing, depreciation, tax and recovery of initial investment. Compare it with safe saleable capacity and repeat the calculation using actual prices, costs and customer mix; negative contribution has no meaningful positive break-even.
What happens if PCJ-23 volume is 20% below the illustration?
Holding unit price and cost unchanged, a 20% volume reduction before whole-unit rounding gives 2,400 billable units, producing an operating cash result of ₹18,000 before financing and tax. The reduction from the base is ₹42,000. This is one sensitivity, not a probability forecast; test simultaneous price pressure, cost increases and slower collection as well.
Why can retail pharmacy & jan aushadhi show profit but run out of cash?
Collection timing, stock, supplier credit, deposits, capex and loan repayment differ from accounting revenue and expense. The example starts with 3 collection days, 45 inventory days and 30 supplier-credit days where the model allocates credit-eligible cost. Replace these with contract evidence; employee and statutory payments must still meet their actual due dates.
Are taxes automatically calculated in the PCJ-23 workbook?
No. Indirect tax is excluded from revenue/cost assumptions except non-creditable amounts that the user should include in cost. Monthly tax cash is a separate editable input and starts at zero only as a placeholder. Determine actual GST, withholding and income-tax obligations from the transaction, tax year and operative provisions before relying on funding outputs.
How should owner salary be handled in PCJ-23?
Include the genuine cost of replacing the founder’s operating work when assessing commercial viability, even if cash drawings are temporarily low. Legal and tax treatment of salary, remuneration or drawings depends on the entity and facts. Do not present a business as profitable solely because the founder’s labour is uncosted.
Which business structure is best for retail pharmacy & jan aushadhi?
Compare ownership, liability, investor needs, professional eligibility, administration, tax and exit rather than selecting a company automatically. Obtain a tailored entity decision and open proper business banking and records. An entity registration identifies the business; it does not grant its sector permissions or eliminate personal professional responsibility.
Which government forms and fees apply to PCJ-23?
Use the permission matrix to identify the actual authority and activity, then obtain that authority’s operative prescribed form and fee assessment. Record entity, State/city, premises, capacity and service categories before applying. The downloadable dossiers are internal working records, not statutory forms; blank fee cells do not mean that no fee is payable.
How should insurance be evaluated for PCJ-23?
Describe the actual activities, people, assets, data and customer exposures to a competent insurance adviser. Compare limits, exclusions, deductibles, claims conditions and continuity cover against contracts and realistic losses. Insurance does not authorise a prohibited activity or replace safety, professional competence or required registration.
When is PCJ-23 ready to expand?
Expand after demand has converted into paid repeat business, safe capacity and staffing are available, compliance conditions are met and the downside cash forecast remains fundable. Use the business-specific metrics in this guide. More leads or higher billed revenue alone do not demonstrate sustainable growth.
What should a founder do before closing PCJ-23?
Use the prescribed change/closure process, arrange lawful transfer or disposal of stock, settle supplier and employee dues, protect prescription records and complete programme exit requirements where relevant. Do not transfer a licence informally with the shop keys. Plan obligations and customer continuity before announcing a closure date; a decision to stop trading does not automatically cancel outstanding licences, contracts, employee dues or tax filings.
Working documents and downloads
- Demand Validation — CSV
- Permission Dossier — CSV
- Fee And Quote Register — CSV
- Unit Cost Sheet — CSV
- Contract Review — CSV
- Operating Control Log — CSV
- Incident And Remedy Log — CSV
- Staff And Competence — CSV
- Receivables And Claims — CSV
- Launch 90 Day Plan — CSV
- Sector Performance Register — CSV
- Closure Transfer Checklist — CSV
Permissions, evidence and financial decision gates
Keep programme eligibility and drug licensing separate
PMBI opening conditions include a registered pharmacist arrangement and premises requirements. The August 2025 opening guide specifies minimum 120 sq. ft. for its programme. That programme condition is not a universal substitute for State drug-licence premises or storage requirements.
Completion evidence: PMBI application, State drug-permission decision, pharmacist registration/coverage and premises evidence.
Reference: PMBI — opening guidelines, published 25 August 2025
Use the later incentive terms, not the old FAQ
The 29 August 2024 circular, effective 1 September 2024, removes the old cumulative Rs 5 lakh ceiling and sets a purchase-linked incentive of 20%, capped at Rs 20,000 per month, subject to conditions. The 2025 guide splits it between purchase and stocking components. It is not guaranteed net profit.
Completion evidence: Applicable circular, signed scheme terms, eligible purchases, PoS stock evidence and received incentive reconciliation.
Reference: PMBI — incentive circular, 29 August 2024, effective 1 September 2024
Budget only scheme fees that actually apply
The registration page specifies a non-refundable Rs 5,000 application fee and exemptions for its stated categories with documentary conditions. Record the exact category and accepted proof. This is not the State drug licence fee, inspection cost, stamp duty, pharmacist cost or total setup cost.
Completion evidence: Official fee demand/exemption decision and receipt; separate State fee and contract-cost rows.
Reference: PMBI — registration and scheme documents
Control medicine quality and pharmacist continuity
Purchase from authorised sources, verify product/batch identity, storage needs and expiry, and record pharmacist presence and substitution. Set a documented stop-dispensing and escalation rule when legal coverage is unavailable. Avoid unsupported therapeutic equivalence or prescription-change advice by unqualified staff.
Completion evidence: Supplier licences/invoices, storage/expiry logs, pharmacist roster, complaint and recall records.
Reference: CDSCO — Drugs Rules and amendments
Distinguish gross margin, incentives and free cash
The opening guide describes a 20% MRP-excluding-tax operating margin. It is before rent, staff, losses and other expenses. Special assistance and monthly incentives have distinct conditions and timing; do not enter them as certain monthly operating cash or as an automatic reduction in startup equity. The August 2025 PMBI guidelines describe 50% advance against proforma invoice before dispatch and balance within 30 days, subject to limits; repeated overdue payments can move supply to 100% advance. Distributor terms may differ. The workbook is a generic retail illustration, not a Jan Aushadhi procurement forecast: replace its supplier-credit assumptions and separately plan advance-payment dates.
Completion evidence: Sales/purchase margin bridge, cost budget, conditional incentive schedule and downside funding plan. Include dated supplier agreement, proforma invoice, advance-payment calendar and credit-limit evidence.
Reference: PMBI — opening guidelines, published 25 August 2025
Procurement and working capital: the PCJ-23 model is a generic retail-pharmacy illustration. Its original supplier-credit assumptions are not PMBI terms. The August 2025 PMBI guidelines describe 50% advance before dispatch and the balance within 30 days, with tighter terms for repeated overdue payments. Model the actual agreement and pre-dispatch timing separately; a 50% credit-share monthly sensitivity is only an approximation. PMBI — opening guidelines, published 25 August 2025
Official references and scope
- PMBI — programme and official noticesProgramme entry point; use the dated opening guidelines and incentive circular for their specific terms.
- CDSCO — Drugs Rules and amendmentsDrug-category and State retail/wholesale licensing route; actual form, fee and current licence conditions must match the activity.
- CDSCO — Medical Devices Rules and amendmentsRules and amendments repository; combine the item classification, actual transaction and State licensing decision.
- Ministry of Labour / PIB — Labour Codes commencement and transition21 November 2025 commencement announcement; the release also preserves relevant existing provisions/rules/schemes during transition.
- CBDT — Income-tax Act, 2025 commencementAct effective 1 April 2026; match the year, operative provisions and forms. This press release is not a transaction-specific tax computation.
- GST Council — central GST legislation and notificationsDiscovery route. The linked 2021 consolidated rules are a historical baseline, not a complete October 2026 consolidation.
- India Code — Consumer Protection Act, 2019Consumer contracts, product/service representations and remedies require the actual law and transaction; broad contractual disclaimers are not approval.
- PMBI — opening guidelines, published 25 August 2025Sections III–V and application requirements: pharmacist, premises, margins, incentives, documentation and programme conditions.
- PMBI — incentive circular, 29 August 2024, effective 1 September 2024Removes cumulative Rs 5 lakh cap and changes purchase-linked incentive; stocking conditions and monthly limit apply.
- PMBI — registration and scheme documentsApplication fee, exemptions, guidelines, agreement and scheme forms; excludes State drug licence fees.
- CDSCO — State and UT Drugs Control directoryIdentify the competent State/UT licensing office; verify its actual current form, fee and contact through official channels.
Read the precise instrument and its amendments for the relevant activity and date. Directory pages are entry points; they are not individual approvals. Government schemes and technical or professional standards do not remove State/city requirements. Information and examples are general education, not individual legal, investment, tax or medical advice.
Continue your business planning
Compare all 28 business playbooks · Search the questions and answers